



# OPTIMIZING OUTCOMES IN OSTEOPOROSIS:

## Effective Strategies for Improving Risk Assessment, Diagnosis, and Treatment Selection

### SUGGESTED READINGS

#### Practice Guidelines

Camacho PM et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2020 Update. *Endocr Pract.* 2020;26(suppl 1):1-47. doi:10.4158/GL-2020-0524SUPPL

Camacho PM et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2020 Update Executive Summary. *Endocr Pract.* 2020;26:564-570. doi:10.4158/GL-2020-0524

International Society for Clinical Densitometry. 2019 ISCD Official Positions: adult. Accessed May 10, 2021. <https://iscd.app.box.com/s/5r713cfzvf4gr28q7zdccg2i7169fv86>

Kanis JA et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int.* 2019;30:3-44. doi:10.1007/s00198-018-4704-5

Kanis JA et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. *Osteoporos Int.* 2020;31:1-12. doi:10.1007/s00198-019-05176-3

#### Reviews

Camacho PM. Updates on Osteoporosis, *An Issue of Endocrinology and Metabolism Clinics of North America*, Volume 50-2. 1st ed. Elsevier; 2021.

Compston JE et al. Osteoporosis. *Lancet.* 2019;393:364-376. doi:10.1016/S0140-6736(18)32112-3

Khan AA et al. Diagnosis of osteoporosis: clinical and densitometric analysis. *Can Assoc Radiol J.* 2021; 72:326. doi:10.1177/0846537120944385

Liu J et al. State of the art in osteoporosis risk assessment and treatment. *J Endocrinol Invest.* 2019; 42:1149-1164. doi:10.1007/s40618-019-01041-6

Seeman E, Delmas PD. Bone quality – the material and structural basis of bone strength and fragility. *N Engl J Med.* 2006;354:2250-2261. doi:10.1056/NEJMra053077

# SUGGESTED READINGS

## Clinical Trials

- Bolognese MA et al. Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study. *J Clin Densitom.* 2003;16:147-153. doi:10.1016/j.jocd.2012.02.006
- Bone HG et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. *J Clin Endocrinol Metab.* 2013;98:4483-4492. doi:10.1210/jc.2013-1597
- Bone HG et al. ACTIVEExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. *J Clin Endocrinol Metab.* 2018;103:2949-2957. doi:10.1210/jc.2018-00163
- Bone HG et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomized FREEDOM trial and open-label extension. *Lancet Diabetes Endocrinol.* 2017;5:513-523. doi:10.1016/S2213-8587(17)30138-9
- Bouxsein ML et al. Change in bone density and reduction in fracture risk: a meta-regression of published trials. *J Bone Miner Res.* 2019;34:632-642. doi:10.1002/jbmr.3641
- Cosman F et al. Romosozumab treatment in postmenopausal women with osteoporosis. *N Engl J Med.* 2016;375:1532-1543. doi:10.1056/NEJMoa1607948
- Cosman F et al. Eighteen months of treatment with subcutaneous abaloparatide followed by 6 months of treatment with alendronate in postmenopausal women with osteoporosis: results of the ACTIVEExtend trial. *Mayo Clin Proc.* 2017;92:200-210. doi:10.1016/j.mayocp.2016.10.009
- Cummings SR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. *N Engl J Med.* 2009;361:756-765. doi:10.1056/NEJMoa0809493
- Kendler DL et al. Effects of teriparatide and risedronate in new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomized, controlled trial. *Lancet.* 2018;391:230-240. doi:10.1016/S0140-6736(17)32137-2
- Kwok TCY et al. Predictors of non-vertebral fracture in older Chinese males and females: Mr. OS and Ms. OS (Hong Kong). *J Bone Miner Res.* 2017;35:330-337. doi:10.1007/s00774-016-0761-z
- Lewiecki EM et al. A phase III, randomized, placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. *J Clin Endocrinol Metab.* 2018;103:3183-3193. doi:10.1210/jc.2017-02163
- Lewiecki EM et al. One year of romosozumab followed by 2 years of denosumab maintains fracture risk reductions: results of the FRAME Extension Study. *J Bone Miner Res.* 2019;34:419-428. doi:10.1002/jbmr.3622
- Miller PD et al. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: results from the ACTIVE phase 3 trial. *Bone.* 2019;120:137-140. doi:10.1016/j.bone.2018.10.015
- Miller PD et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. *JAMA.* 2016;316:722-733. doi:10.1001/jama.2016.11136
- Saag K et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. *N Engl J Med.* 2017;377:1417-1427. doi:10.1056/NEJMoa1708322
- Watts NB et al. Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVEExtend phase 3 trial. *Osteoporos Int.* 2021;32:55-61. doi:10.1007/s00198-020-05555-1